Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

We are asked many times about, what’s your thought about Dupixent and its approval and its impact on Eutrovera use. And I really it’s really no impact. And in many ways, we find it to be complementary ...

The comparable figures from Dupixent trials are as high as 36% after 16 weeks. Amgen sees an opportunity for a drug with a different mechanism of action, citing evidence about how often patients ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...